Moderna will present safety data on Wednesday from an early trial that provides the first glimpse of how its Covid-19 vaccine stimulates the immune system in older people.
The company will present “new interim safety and immunogenicity data from the cohorts of older adults” from its phase 1 trial, according to a statement. The results will be presented to the US Center for Disease Control and Prevention’s Advisory Committee on Immunisation Practices. The company earlier published data from the same trial showing that the vaccine produced neutralising antibodies against the coronavirus in younger adults. .
The Moderna vaccine is now in a large, final-stage trial in the US, with results possible by late fall. Moderna shares rose as much as 3.1% in premarket trading in New York.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
WATCH: How Covid-19 sent Absa’s earnings slidingFinancial director Jason Quinn talks to Business Day TV about the bank’s performance
Herkunft: BDliveSA - 🏆 12. / 63 Weiterlesen »